Michael Lusiola named Kenya BioVax Institute CEO

Kenya BioVax Institute’s Board of Directors Chairman Mugo Kibati on Monday stated that Dr. Lusiola's appointment takes effect immediately.

"We are confident that, after a competitive recruitment process, we have found in Dr. Lusiola a healthcare and business leader who will head the organization with distinction, scientific innovation, commercial business acumen and integrity,” said Mr. Kibati.

The senior healthcare executive takes over from Dr. Rabera Kenyanya who has been the Acting CEO from December 2021.

“We are truly grateful for the exemplary work done by Dr. Rabera during her role in an acting capacity," added the Chairman.

Dr. Lusiola attained his graduate and post-graduate academic qualifications from Harvard University (post-graduate, global public health) and the University of Reading (post-graduate, business management and administration).

He also holds post-graduate qualifications from the University of Liverpool and Aston University, as well as a graduate qualification in Pharmacy from the University of Nairobi.

He has memberships at the Institute of Clinical Research (MICR) UK, the Royal Society of Medicine (MRSM) UK, the Royal Pharmaceutical Society (MRPS) UK, and the International Society for Vaccines.

Dr. Lusiola’s appointment comes at a time when The BioVax Institute is undergoing inception, with the primary mandate to manufacture and commercialize specialized human health products and technologies (HPTs).

This includes vaccines, gene therapies and assistive medical and diagnostic devices.